(2S)-2-羟基-3-甲基丁酸钙 | 57618-22-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: (2S)-2-羟基-3-甲基丁酸钙
• 英文名称: Calcium bis((S)-2-hydroxy-3-methylbutyrate)
• 英文别名: calcium;(2S)-2-hydroxy-3-methylbutanoate
• CAS: 57618-22-1
• 化学式: C10H18CaO6
• 分子量: 274.32
• InChiKey: CLWNJPHDLVMMEU-SCGRZTRASA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -2.87
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  121
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• THERAPEUTIC AGENTS 414
  申请人：BENNETT Stuart Norman Lile

  公开号：US20100093757A1

  公开（公告）日：2010-04-15

  A compound of Formula (I): is useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK or GK), leading to a decreased glucose threshold for insulin secretion.

  化合物Formula (I)在通过葡萄糖激酶（GLK或GK）介导的疾病或医疗状况的治疗或预防中很有用，导致胰岛素分泌的葡萄糖阈值降低。
• Detection and Quantitation Method for Proteomics of Post-Translational Modifications
  申请人：Sichuan University

  公开号：US20200033361A1

  公开（公告）日：2020-01-30

  The present disclosure relates to the technical field of comparative proteomics, in particular to a detection and quantitation method for proteomics of post-translational modifications. With this method, the protein samples to be studied and internal standards are labeled with isobaric tandem mass tags, and tandem mass spectrometry analysis is carried out for the labeled peptide mixture, wherein the internal standard is a peptide mixture rich in post-translational modifications to be detected. Through this method, the signal of peptides containing the post-translational modifications to be detected can be amplified under the situation that mass spectrometer sensitivity is unchanged, and enrichment of the post-translational modification peptides is not needed. The probability of detecting the peptides containing the post-translational modifications to be detected by mass spectrometer and being selected for subsequent MS/MS analysis is increased.
• US8143263B2
  申请人：——

  公开号：US8143263B2

  公开（公告）日：2012-03-27
• [EN] THERAPEUTIC AGENTS 414<br/>[FR] AGENTS THÉRAPEUTIQUES 414
  申请人：ASTRAZENECA AB

  公开号：WO2010015849A2

  公开（公告）日：2010-02-11

  A compound of Formula (I) is useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK or GK), leading to a decreased glucose threshold for insulin secretion.